Dapagliflozin – Medxy AI

Cellular Adhesion Molecules as Prognostic Biomarkers and Therapeutic Insights in Chronic Heart Failure: Integrative Review Emphasizing DAPA-HF Findings

By MedXY 12/03/2025

Elevated VCAM-1 levels correlate with worse outcomes in chronic HFrEF, independent of conventional markers; dapagliflozin’s benefits are consistent across VCAM-1 levels, highlighting inflammatory pathways as therapeutic targets.

Diabetes & Endocrinology Nephrology news

Balcinrenone plus Dapagliflozin Reduces Albuminuria in CKD: MIRO‑CKD Phase 2b Shows Dose‑Dependent Benefit with Acceptable Safety

By MedXY 11/28/2025

The MIRO‑CKD phase 2b trial found that adding the non‑steroidal MRA balcinrenone to dapagliflozin reduced albuminuria versus dapagliflozin alone in people with CKD, with dose‑dependent effects and modest hyperkalaemia rates over 12 weeks.

Nephrology news Rheumatology

Evaluating Dapagliflozin’s Impact on Bone Health in Lupus Nephritis: Insights from a Double-Blind, Placebo-Controlled Trial

By MedXY 10/30/2025

This RCT shows dapagliflozin does not significantly affect bone metabolism or mineral density in lupus nephritis patients over 12 months, alleviating concerns about SGLT2 inhibitors' bone safety in this population.

Cardiology Nephrology news

Dapagliflozin and Cardiac Remodeling in Chronic Kidney Disease: New Evidence for Cardioprotection

By MedXY 10/30/2025

Dapagliflozin reduces left ventricular mass index in chronic kidney disease patients, revealing a key mechanism for cardioprotective effects of SGLT2 inhibitors and highlighting early treatment benefits.

Clinical Updates news

Dapagliflozin’s Effects on Hormonal Regulation and Ketone Production in Adults with Type 1 Diabetes: Insights from a Randomised Controlled Crossover Trial

By MedXY 09/17/2025

This trial evaluates dapagliflozin's impact on key hormones and ketogenesis in type 1 diabetes, demonstrating increased ketone bodies without altering GLP-1, glucagon, or somatostatin secretion, highlighting risks and benefits for adjunct therapy.

Cardiology Diabetes & Endocrinology Specialties

Dapagliflozin in Hospitalized Heart Failure Patients: Insights from the DAPA ACT HF-TIMI 68 Trial and Meta-Analysis

By MedXY 09/07/2025

In-hospital initiation of dapagliflozin showed a non-significant reduction in cardiovascular death or worsening heart failure at two months. However, meta-analysis supports early SGLT2 inhibitor use for reducing mortality and worsening HF in hospitalized patients.

Clinical Updates Diabetes & Endocrinology Specialties

Enhancing Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes: Insights from Dapagliflozin and Exenatide Combination Therapy

By MedXY 08/23/2025

Dapagliflozin and exenatide independently improve beta-cell function and insulin sensitivity in type 2 diabetes; their combination markedly enhances these effects, suggesting superior glycemic control potential.

Clinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

Dapagliflozin Shows Promising Benefits for Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Landmark Multicentre Trial

By MedXY 08/13/2025

Dapagliflozin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis outcomes without increasing adverse events, according to a rigorous 48-week randomized trial.

Clinical Updates Diabetes & Endocrinology Neurology news Specialties

Impact of Dapagliflozin on Cognitive Function in Older Adults with Type 2 Diabetes and Mild Cognitive Impairment

By MedXY 08/11/2025

A 36-week study shows that dapagliflozin significantly improves cognitive function and metabolic parameters in middle-aged and older patients with type 2 diabetes and mild cognitive impairment.